Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Nikkomycin Z Bioavailability Under Fed and Fasting Conditions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be at least 18 years of age and not over 40 years of age~* Be male, or female (non childbearing potential or using adequate contraception)~* Have a body mass index between 18 and 29 kg/m2~* Able to understand the study and give written informed consent~* Be determined healthy based on a medical and laboratory evaluation~Exclusion Criteria:~* Patients under the age of 18 years or over 40 years of age~* Current smoker or history of smoking within 3 months of participation~* Inability to comprehend study and provide written informed consent~* Inability to comply with the study requirements~* History of or current evidence of major organ disease~* Renal disease - serum creatinine \> 1.5 mg/dL, significant hematuria or proteinuria, known structural abnormality or chronic kidney disease~* Hepatic disease - active viral hepatitis, history of hepatitis B or hepatitis C, bilirubin \> 2.0, ALT or AST above normal upper limit for laboratory, alcoholic liver disease, other chronic liver disease~* CNS disease or cognitive dysfunction - any past history of epilepsy, CNS infections, stroke, CNS bleed, severe headaches, major psychiatric illness, or current mental status changes~* Lung disease - history of severe asthma, COPD, pulmonary tuberculosis, or other major lung disease~* Cardiac disease - history or current evidence of ischemic coronary artery disease, myocardial infarction, heart failure, or significant arrhythmia~* Gastrointestinal disease - presence of inflammatory bowel disease, difficulty swallowing, or any gastrointestinal probably that would limit taking oral medications or that may compromise absorption of oral medications~* Cancer - History of hematologic malignancy or solid tumor excluding basal cell carcinoma limited to the skin within the past 5 years~* History of autoimmune or inflammatory disease such as rheumatoid arthritis and lupus~* Immunocompromised state - solid organ transplant, cancer chemotherapy, stem cell transplant with graft versus host disease, immunosuppressive therapy, or HIV infection~* Recent weight loss of greater than 10%~* Any other history or evidence of disease that in the opinion of the physician would increase the risk for the subject for clinical trial participation~* Regular use of prescription medications, over-the-counter medications, or dietary/herbal supplements within 14 days of day 1. Occasional use of acetaminophen or over-the-counter NSAID within the 14 day window may be allowed at the P.I. discretion~* Subjects who received another investigational drug within 30 days of enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Nikkomycin Z fed - fasting (Type: EXPERIMENTAL): Period 1:~* Day 1: Nikkomycin Z 500 mg with high fat breakfast~Period 2:~* Day 1: Nikkomycin Z 500 mg under fasted conditions
- Nikkomycin Z fasting - fed (Type: EXPERIMENTAL): Period 1:~* Day 1: Nikkomycin Z 500 mg under fasted conditions~Period 2:~* Day 1: Nikkomycin Z 500 mg with high fat breakfast

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues